Merck & Co shares climbed another 2.83% today to $154.94, hitting a new 52-week high of $155.10 and extending a rally that has added 45% to the share price year to date. The move comes as investors continue to reprice the Keytruda franchise in light of a landmark Phase 3 melanoma trial win, and it raises a pointed question: how much of the good news is already in the stock?
The rally appears to reflect the market’s ongoing effort to value something genuinely new. Last week (August 19), Merck and Moderna announced that intismeran autogene, an individualized mRNA cancer vaccine, improved recurrence-free survival and distant-metastasis-free survival versus Keytruda alone in the 1,137-patient INTerpath-001 study. No new safety concerns emerged. It was the first positive late-stage readout for an mRNA-based cancer vaccine used alongside checkpoint inhibition, and the market treated it accordingly, sending Merck up roughly 12.6% on the day of the announcement. Today’s follow-through suggests that repricing is not finished.
The strategic logic is straightforward. Keytruda generated approximately $31.6 billion in 2025 sales, close to half of Merck’s total revenue. The drug’s primary compound patent in the United States expires in December 2028, and biosimilar competition has already begun in some international markets. A personalized vaccine combination that demonstrably improves outcomes on top of Keytruda gives the franchise a layer of clinical differentiation that biosimilars cannot easily replicate. Merck is already studying intismeran combinations in non-small cell lung cancer, bladder cancer, and renal-cell carcinoma, meaning the melanoma result could be the first data point in a multi-indication platform rather than a single-market win.
That platform argument is what the tape is pricing. CEO Rob Davis has pointed to more than $70 billion of commercial opportunity across more than 20 new products, and the pipeline extends well beyond oncology, with WINREVAIR posting strong early sales growth and newer launches adding diversification. The intismeran result strengthens the narrative that Merck can sustain growth through and beyond the Keytruda patent transition rather than simply managing a decline.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The broader market backdrop may also be helping. Capital has been rotating out of data-center and hyperscaler names into healthcare and enterprise software, a shift driven partly by bond market volatility and partly by political friction around data center construction in several states. Within healthcare, Merck occupies an unusual position: it carries the defensive characteristics of a large-cap pharma name, including a low and slightly negative beta relative to the S&P 500, while simultaneously offering a genuine growth story tied to pipeline milestones. That combination is drawing investors who want healthcare exposure without sacrificing upside.
View From The Street
Price Targets
The consensus picture among 26 analysts is constructively positive but not euphoric. Twelve carry strong buy ratings, three have buys, and eleven are at hold, producing an average rating score of roughly 4.0. The average price target sits at $147.77, which is now about 4% below today’s price. That gap matters. The melanoma data arrived after most of those targets were set, and the tape has moved faster than formal sell-side updates.
Bullish models have cited targets in the $172 to $195 range in some cases, but the consensus has not yet caught up. That creates room for upgrades to act as a secondary catalyst, but it also means the stock is currently trading above where the average analyst thought fair value sat before the trial results were published.
Technical Read
The technical picture is unambiguous about trend direction and equally clear about overextension. The moving-average stack is firmly bullish: price at $154.18 sits well above the 50-day simple moving average of $128.58, which in turn sits above the 200-day at $114.57. The 20-day exponential moving average of $137.66 is above the 50-day EMA of $130.37. Trend strength is genuine, with the ADX reading at 34.92 and rising, indicating that momentum is building rather than fading.
The overbought signals are equally clear. The 14-period RSI stands at 73.7, and the CCI confirms the stretch at 160.3. Price has pushed above the upper Bollinger Band, which sits at $151.96, with band width expanding to nearly 25% and 20-day volatility rising sharply. These readings are consistent with a momentum extension in a strong trend, not with a reversal, but they do raise the probability of a pause or consolidation before the next leg. The gap-up origin zone around $146 to $147 represents a natural support level if profit-taking materializes.
